ৰেক্তেল কেন্সাৰ
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
ক’ত যাব
এই ট্ৰায়েলৰ বাবে ভাৰতৰ 8 খন হস্পিটেলত ৰোগী লোৱা হৈছে।
ৰেজিষ্ট্ৰীৰ সাৰাংশ (কাৰিকৰী)
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectabl…
স্পন্সৰ: জেনচেন ৰিচাৰ্চ এণ্ড ডেভেলপমেণ্ট, LLC
ClinicalTrials.gov-ত NCT06750094
ৰেজিস্ট্ৰীত অন্তিমবাৰ আপডেট কৰা হৈছে 25 ছেপ্টেম্বৰ 2026 · আমি পঢ়িছোঁ 20 অক্টোবৰ 2026